MET and ovarian carcinoma: Many of these agents have been tested in pre-clinical models of ovarian cancer including PF-2341066 (c-MET-specific), Foretinib (c-MET and VEGFR-2), MK8033 (c-MET specific), DCC-2701 (c-MET/Tie-2/VEGFR-2), and SU11274 (c-MET specific) and lead to decreased cell motility and invasion, reduced adhesion and peritoneal dissemination, as well as reductions in tumour burden in treated cells and animals20, 21, 22, 23, 24.